In a surveillance analysis of patients receiving curative intent treatment for CRC, Guardant Reveal predicted distant recurrence with up to 91% sensitivity.²*
Achieve high sensitivity using combined genomic and epigenomic signals.¹
Explore how Guardant Reveal maximizes sensitivity in breast cancer surveillance.³
CRC, colorectal cancer.
Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.
*Sensitivity was calculated based on samples collected before or at recurrence.
Home Oncology Portfolio Partnerships European Policy Guardant Infinity™ for BioPharma